A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

scientific article published on 21 August 2015

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.18632/ONCOTARGET.4905
P932PMC publication ID4745707
P698PubMed publication ID26338962
P5875ResearchGate publication ID281540987

P50authorOrit ItzhakiQ92180479
Gal MarkelQ102132203
Liat AnafiQ114337209
Eyal GreenbergQ115760801
Yael NemlichQ115760802
Gilli Galore-HaskelQ115760805
Jacob SchachterQ55651283
P2093author name stringMichal J Besser
Motti Hakim
Eytan Ben-Ami
Efrat Ofek
Shira Ashkenazi
Noa Shoshani
Ronnie Shapira-Fromer
P2860cites workADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencingQ24339141
ADAR1 interacts with NF90 through double-stranded RNA and regulates NF90-mediated gene expression independently of RNA editingQ24529861
The role of microRNA genes in papillary thyroid carcinomaQ24535848
RNA editing of a miRNA precursorQ24540290
Modulation of microRNA processing and expression through RNA editing by ADAR deaminasesQ24594425
miR-221 suppresses ICAM-1 translation and regulates interferon-gamma-induced ICAM-1 expression in human cholangiocytesQ24597200
Frequency and fate of microRNA editing in human brainQ24653250
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerQ27860857
Widespread changes in protein synthesis induced by microRNAsQ27860886
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaQ27861062
Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanomaQ28116578
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaQ28131634
Editing independent effects of ADARs on the miRNA/siRNA pathwaysQ28256753
ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signalingQ28591461
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerQ29615679
Redirection of silencing targets by adenosine-to-inosine editing of miRNAsQ29619387
Systematic identification of abundant A-to-I editing sites in the human transcriptomeQ29619584
Systemic dysregulation of CEACAM1 in melanoma patientsQ84295467
Genetic basis for clinical response to CTLA-4 blockade in melanomaQ29620594
Widespread RNA editing of embedded alu elements in the human transcriptomeQ31108738
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.Q31115813
Regulation of cancer aggressive features in melanoma cells by microRNAsQ33889489
The synapse and cytolytic machinery of cytotoxic T cellsQ33913834
Expression profiling identifies microRNA signature in pancreatic cancerQ34588109
Melanoma epidemiology and public health.Q34605024
The structure, regulation, and function of ZAP-70.Q34605479
Immune escape of tumors: apoptosis resistance and tumor counterattack.Q34671704
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanismsQ34770421
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.Q34986356
A-to-I RNA editing: recent news and residual mysteriesQ35006724
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.Q35617517
Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune responseQ36192088
Adoptive cell therapy for the treatment of patients with metastatic melanomaQ36283034
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growthQ36890980
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignanciesQ37000638
How tumours escape mass destructionQ37287162
Adenosine-to-inosine RNA editingQ37787949
Melanoma-associated antigen genes – An updateQ37811276
The mechanisms of cancer immunoescape and development of overcoming strategiesQ37849666
A-to-I RNA editing: the "ADAR" side of human cancerQ37935255
Raising the bar: the curative potential of human cancer immunotherapy.Q37998451
Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of actionQ38012626
The influence of ADAR1's regulation on lymphocyte cell function during rejectionQ38350496
Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactionsQ39371179
ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathwayQ39910342
Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactionsQ40216992
Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammationQ41412859
Roles for microRNAs in the regulation of cell adhesion moleculesQ41987634
RNA editing of human microRNAsQ42113662
Spontaneous regression of melanomaQ43944488
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapiesQ45838316
Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attackQ47632531
An immune-active tumor microenvironment favors clinical response to ipilimumabQ56898024
Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulationQ73838333
P4510describes a project that usesImageQuantQ112270642
P433issue30
P407language of work or nameEnglishQ1860
P304page(s)28999-29015
P577publication date2015-08-21
P1433published inOncotargetQ1573155
P1476titleA novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
P478volume6

Reverse relations

cites work (P2860)
Q26773402A-to-I editing of coding and non-coding RNAs by ADARs
Q92593887ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications
Q61813334ADAR1 Editing and its Role in Cancer
Q91964806ADAR1 promotes the epithelial-to-mesenchymal transition and stem-like cell phenotype of oral cancer by facilitating oncogenic microRNA maturation
Q99241375ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family members
Q55026245ADAR1-mediated regulation of melanoma invasion.
Q37699205Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling
Q42369277Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
Q28078188Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases
Q47160476Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma.
Q47225399Ipilimumab for the treatment of metastatic prostate cancer
Q61417351MiRNAs in Malignant Melanoma
Q90080352Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma
Q95276547Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy
Q60949658The Role of RNA Editing in Cancer Development and Metabolic Disorders
Q46803210miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer
Q47152593miRNAs, Melanoma and Microenvironment: An Intricate Network
Q37197466microRNA editing in seed region aligns with cellular changes in hypoxic conditions

Search more.